

Friday, May 12, 2017

7:30 AM – 1:00 PM

Boston Marriott Copley Place, Boston, Massachusetts

Prostate Cancer State of the Art — State of the Disease

We are pleased to present the 20th anniversary prostate cancer symposium featuring keynote speakers from the last 20 years! These outstanding individuals will discuss “State of the Art — State of the Disease” in three separate panels that highlight how the diagnosis, treatment and research on prostate cancer have evolved — and what the future holds.

Don't miss this outstanding event especially designed for men-at-risk, newly diagnosed, survivors, and their families. Primary care doctors are also encouraged to attend.

The symposium includes three panels featuring leaders in the field of prostate cancer.

- **Prevention and Screening**

Peter C. Albertsen, MD, *UConn Health Center*

J. Jacques Carter, MD, *Beth Israel Deaconess Medical Center*

Marc B. Garnick, MD, *Beth Israel Deaconess Medical Center*

Andrew Vickers, Ph.D., *Memorial Sloan Kettering Cancer Center*, moderator

- **Active Surveillance and Early Stage Disease**

Clair J. Beard, MD, *Brigham and Women's Hospital/
Dana-Farber Cancer Institute*

Adam S. Kibel, MD, *Brigham and Women's Hospital*

Eric A. Klein, MD, *Cleveland Clinic*

Laurence Klotz, MD, *University of Toronto*, moderator

Clare M. Tempany, MD, *Brigham and Women's Hospital*

- **Metastatic Disease and Research**

Glenn Bubley, MD, *Beth Israel Deaconess Medical Center*, moderator

William G. Nelson, MD, *Johns Hopkins University School of Medicine*

Susan F. Slovin, MD, *Memorial Sloan Kettering Cancer Center*

**2017
Award
Recipients**

Charles Austin Award for Outstanding Service in Prostate Cancer Awareness



Established in 2006 to honor Charles Austin, an outstanding member of MPCC's first board of directors, this year's Austin Award will be presented to **Stan and Fran Klein**, longtime advocates and support group leaders.

Jack Colbert Memorial Award

Established in 2008 to honor a founding member of MPCC, the Colbert Award is presented periodically to a distinguished individual in the medical community who has significantly advanced the fight to conquer and cure prostate cancer through research and/or practice.



This year's recipient is **Marc B. Garnick, MD**, an internationally renowned expert in medical oncology and urologic cancer at Beth Israel Deaconess Medical Center and the Gorman Brothers Professor of Medicine at Harvard Medical School.

Sponsors to Date

Bayer Healthcare
Beth Israel Deaconess Medical Center
Brigham and Women's Hospital
Dana-Farber Cancer Institute
David Godkin
Garth and Lindsay Greimann
Greater Boston Urology
Massachusetts Prostate Cancer Coalition
Peter O'Connell
Richard Parker
Allen L. Snyder III

EDUCATIONAL GRANTS

AdMeTech Foundation
Cancer Research Foundation / ZERO
Genomic Health
Million Dollar Roundtable (MDRT) Foundation

Symposium Schedule

7:30AM Registration and Breakfast

8:00 Greetings and Welcome

8:15 Panel on Prevention and Screening

Prostate cancer is one of the few cancers that we know how to detect early (via PSA testing) and prevent (with drugs like finasteride). Yet it is far from clear that doing so does more good than harm: PSA testing has led to massive over diagnosis and overtreatment, and prevention has not become widespread due to concerns that finasteride lowers the risk of indolent, but not aggressive, disease.

The panel will focus on how to ensure that we practice medicine in such a way to maximize benefits and minimize harms of prostate cancer screening and prevention.

Peter C. Albertsen, MD, J. Jacques Carter, MD, Marc B. Garnick, MD, Andrew Vickers, Ph.D., moderator

9:30 Break

9:45 Panel on Active Surveillance and Early Stage Disease

Active surveillance has become widely utilized for low-risk prostate cancer and has evolved significantly over the last two decades. However, many important questions and controversies remain. Can we define the molecular events that signal “progression” of low-grade disease? How to optimally identify the “wolves in sheep's clothing,” i.e., those men who benefit from early treatment? How best to integrate MRI and biomarkers into treatment decision making? Which intermediate risk patients are candidates for surveillance?

What interventions (diet, exercise, micronutrients, pharmacologic agents) are warranted to reduce the risk of biological progression? What is the most efficient and cost-effective way to follow patients longitudinally? Is serial biopsy still required, and in whom?

Clair J. Beard, MD, Adam S. Kibel, MD, Eric A. Klein, MD, Laurence Klotz, MD, moderator; **Clare M. Tempany, MD**

11:00 Break

11:15 Presentation of Austin and Colbert Awards

Charles Austin Award presented to **Fran and Stan Klein.**

Jack Colbert Memorial Award presented to **Marc Garnick, MD.**

11:30 Panel on Metastatic Disease and Research

Metastatic prostate cancer is the second-leading cause of cancer-related death among men in the United States, responsible for more than 25,000 deaths per year. While the disease remains incurable, meaningful strides have been made recently in its treatment and in understanding of prostate cancer biology. One important revelation is the importance of androgen signaling even after the disease proves refractory to first-line hormonal therapy. This has led to development of effective new agents that form the backbone of modern treatment.

Further discoveries in the areas of radiopharmaceuticals, immunotherapy and targeted therapy based on tumor genetics are broadening the prostate cancer armamentarium. The panel will focus on the latest developments in management of advanced prostate cancer.

William G. Nelson, MD, Susan F. Slovin, MD, Glenn J. Bubley, MD, moderator

1:00PM Closing



2013 KEYNOTE

Peter C. Albertsen, MD is professor of surgery and division chief, program director at the University of Connecticut Health Center in Farmington, CT. He is a trustee of the American Board of Urology.



Clair J. Beard, MD is associate professor of radiation oncology at Harvard Medical School and vice chair of genitourinary radiation oncology at Dana-Farber Cancer Institute. She is on staff at Brigham and Women's Hospital.



Glenn J. Bubley, MD is director of the Division of Genitourinary Medical Oncology at the Beth Israel Medical Center. He is also co-principal investigator for the prestigious Prostate SPORE (Specialized Programs of Research Excellence) at the Dana Farber/Harvard Cancer Center.



J. Jacques Carter, MD, MPH is on staff at Beth Israel Deaconess Medical Center. He is the 2015 recipient of the Jack Colbert Memorial Award.



2012 KEYNOTE

Marc B. Garnick, MD is on staff at Beth Israel Deaconess Medical Center and the Gorman Brothers Professor of Medicine at Harvard Medical School. He is the 2017 recipient of the Jack Colbert Memorial Award.



Adam S. Kibel, MD is chief of Urologic Surgery at Brigham and Women's Hospital and Disease Center Leader (Urology) at Dana-Farber Cancer Institute. He is also a professor of surgery at Harvard Medical School.

Panelists subject to change.

The Massachusetts Prostate Cancer Coalition

(MPCC) educates, connects, and supports men-at-risk, newly diagnosed individuals, survivors, and their families. It also connects organizations and professionals in Massachusetts that seek to conquer and cure prostate cancer.

Symposium Presenters



2012 KEYNOTE

Eric A. Klein, MD is chairman of the Glickman Urological and Kidney Institute at the Cleveland Clinic. He is an international leader in the biology and management of prostate cancer.



2007 KEYNOTE

Laurence Klotz, MD is past chief of urology at Sunnybrook Health Sciences Centre and a professor of surgery at the University of Toronto. He is chairman of the World Urological Oncology Federation and the associate editor of the *Journal of Urology*, responsible for prostate cancer.



2006 KEYNOTE

William G. Nelson, MD, Ph.D. is the Marion I. Knott Director and professor of oncology and director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He is the co-discoverer of the most common genome alteration in prostate cancer.



2008 KEYNOTE

Susan F. Slovin, MD, Ph.D. is a medical oncologist at Memorial Sloan Kettering Cancer Center, specializing in bladder and prostate cancer.



Claire M. Tempany, MD is professor of radiology at Harvard Medical School and Ferenc Jolesz Chair of Research, Radiology at Brigham and Women's Hospital. Her major areas of research interest are MR imaging of the pelvis (specifically prostate cancer) and image-guided therapy.



2016 KEYNOTE

Andrew Vickers, Ph.D. is attending research methodologist at Memorial Sloan Kettering Cancer Center. His research falls into three broad areas: randomized trials, surgical outcomes research, and molecular marker studies. A particular focus of his work is the detection and initial treatment of prostate cancer.

The Symposium has been held annually since 1997. More than 7000 people have attended the annual symposium.

Registration Form

20th Anniversary Massachusetts Prostate Cancer Symposium

PLEASE REGISTER BY MAY 1, 2017

MAIL your completed registration form to:
MPCC, c/o Green Associates, 200 Lincoln St., #201, Boston, MA 02111
FAX: 617.482.3049 ONLINE AT www.masspcc.org
For more information, call 617.482.3044 x28 or email info@masspcc.org

REGISTRATION INFORMATION

Name _____

Organization, if applicable _____

Address _____

City / State / Zip _____

Phone _____

Email _____

Spouse/Companion (Name, if attending) _____

Email _____

Yes, I/we want to attend the 20th Anniversary Massachusetts Prostate Cancer Symposium on Friday, May 12, 2017 at the Boston Marriott Copley Place. There is no fee for the Symposium or breakfast, but attendees are invited to make voluntary contributions of \$25 to partially underwrite the symposium costs.

CONTRIBUTIONS

- \$25 for breakfast (optional)
- \$60 (includes one-year membership in MPCC)
- \$_____ Other amount

TOTAL \$ _____

TO REGISTER ONLINE, [CLICK HERE](#)

ENCLOSED IS MY CHECK: (Checks should be made payable to MPCC and mailed to the address above.)

PLEASE CHARGE MY: MC VISA AMERICAN EXPRESS

Card # _____

Exp. Date _____

CSC _____

Print Name on Card _____

Signature _____

Gifts to the Massachusetts Prostate Cancer Coalition, a 501 (c)(3) public charity, may be tax deductible to the extent allowed by law. (MPCC Tax ID: 04-6946891)

Massachusetts Prostate Cancer Coalition

EDUCATE | INFORM | ADVOCATE

c/o Green Associates
200 Lincoln St., #201
Boston, MA 02111

20 Massachusetts Prostate Cancer Coalition 2017 ANNIVERSARY SYMPOSIUM

Leading prostate cancer specialists provide
up-to-date information on the latest in
prostate cancer diagnosis, treatment and
research — in user-friendly language!

Honorary
Committee

Plan to attend!

20TH ANNIVERSARY MASSACHUSETTS PROSTATE CANCER SYMPOSIUM

Friday, May 12, 2017

7:30 AM – 1:00 PM

**Boston Marriott Copley Place
Boston, Massachusetts**

20 Massachusetts Prostate Cancer Coalition 2017 ANNIVERSARY SYMPOSIUM

Tania Barber, *Caring Health Center*

Anita Christie, *Massachusetts Department of Public Health*

Juan Cofield, *New England Area Conference, NAACP*

Antonio Delesline, *MOCHA*

Thomas Farrington, *Prostate Health Education Network, Inc. (PHEN)*

Rep. Russell Holmes, *Commonwealth of Massachusetts*

Philip Kantoff, MD, *Memorial Sloan Kettering Cancer Center*

Toni McGuire, *Edward M. Kennedy Community Health Center*

Myechia Minter-Jordan, MD, *Dimock Street Community Health Center*

Bill Rodgers, *Four-time winner of the Boston Marathon*

William Shipley, MD, *Massachusetts General Hospital*

Faina Shtern, MD, *AdMeTech Foundation*

Frederica Williams, *Whittier Street Community Health Center*